All Posts

IgA Nephopathy Market | IgAN Market
Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the IgA Nephropathy Market Share Growth

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. Factors such as population aging, lifestyle-modifiable risk factors, a decline in early-life infectious diseases, sedentary lifestyle, unhealthy food habits have resulted in the emergence of chronic diseases as a major global hea...

Find More

pharma-biotech-news-updates-for-novartis-boston-scientific-boehringer-ingelheim
Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical

Boston Scientific pays USD 336 Million to acquire blood clot medical device firm Boston Scientific Corp. is shelling out as much as USD 336 million to take over the rest of medical device firm Devoro Medical, which it has held a stake in since 2019. The payment comprises USD 269 million paid upfront for the 8...

Find More

Healthcare-Data-Breaches-Rising-Threat-Key-Companies-USA-and-Global-Cases-2020-2021
Healthcare Data Breach: What it Means for Companies and the Consumer?

Data and analytics today are playing a major role in the organization’s growth. Stakeholders in a business environment such as companies, investors, and individuals deal with some or other kind of data in their day-to-day life. The data is key to the business prediction that helps to analyze consumer behavior. Comp...

Find More

pharma-biotech-news-updates-for-biogen-smartlabs-synlogic-partner-therapeutics
Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain

Win-win for Biogen as its Biosimilar Gets Approval for AMD  Samsung Bioepis and Biogen's biosimilar drug, Byooviz, received USFDA approval for the treatment of vision loss, Age-related macular degeneration and has become the first biosimilar to Lucentis in the AMD market. The Lucentis copycat had also manag...

Find More

onychomycosis-market-CAGR-size-share-trends-growth-population-epidemiology-therapy-therapeutics-treatment
Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space

Onychomycosis is the most commonly prevalent nail infection in adults. It is a fungal infection that leads to discoloration and thickening of the nail plate. It is four to seven times more frequent in toenails, where it often involves several nails. It is a progressive disease and may become widely spread to other ...

Find More

follicular-lymphoma-market-size-share-trends-growth-cagr-population-epidemiology-therapy-therapeutics-treatment
Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets

Follicular lymphoma, a sub-type of indolent B cell non-Hodgkin lymphoma (NHL), accounts for approximately 20% of the total NHL cases. It is the most frequently diagnosed indolent lymphoma. On average, each year, 15,000 new Follicular lymphoma cases are diagnosed in the US alone. DelveInsight estimated that in 2020 ...

Find More

pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics
FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Find More

Healthcare-Medical-applications-Apps-benefits-disadvantages-types-future-outlook-growth-key-companies
How Healthcare Apps are Adding New Perspectives to the Healthcare Industry?

The mobile app is one of the fine examples of communications systems. The mobile app comes in various forms and formats to meet the various needs of the user. We have moved so much over a short period that it is extremely difficult to imagine a day without using smartphones or tablet PCs and the apps in it. For eve...

Find More

recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma
ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series ...

Find More

oncology-based-indications
Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis

Oncology deals with the diagnosis and treatment of cancer. It is one of the most dynamic segments moving at a rapid pace in terms of research and development activities, diagnostics, and treatment. Oncology encompassed several diseases (or indications). Oncology Based Indications are further classified as Blood can...

Find More